Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
Identifieur interne : 001280 ( Main/Exploration ); précédent : 001279; suivant : 001281Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
Auteurs : Connie Marras [Canada] ; Nathan Herrmann ; Geoffrey M. Anderson ; Hadas D. Fischer ; Xuesong Wang ; Paula A. RochonSource :
- The American journal of geriatric pharmacotherapy [ 1876-7761 ] ; 2012.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antipsychotic Agents (administration & dosage), Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Benzodiazepines (administration & dosage), Benzodiazepines (adverse effects), Benzodiazepines (therapeutic use), Cohort Studies, Dementia (drug therapy), Dibenzothiazepines (administration & dosage), Dibenzothiazepines (adverse effects), Dibenzothiazepines (therapeutic use), Dose-Response Relationship, Drug, Female, Humans, Incidence, Male, Parkinson Disease, Secondary (chemically induced), Proportional Hazards Models, Quetiapine Fumarate, Retrospective Studies, Risk Factors, Risperidone (administration & dosage), Risperidone (adverse effects), Risperidone (therapeutic use), Sex Factors.
- MESH :
- chemical , administration & dosage : Antipsychotic Agents, Benzodiazepines, Dibenzothiazepines, Risperidone.
- chemical , adverse effects : Antipsychotic Agents, Benzodiazepines, Dibenzothiazepines, Risperidone.
- chemical , therapeutic use : Antipsychotic Agents, Benzodiazepines, Dibenzothiazepines, Risperidone.
- chemically induced : Parkinson Disease, Secondary.
- drug therapy : Dementia.
- Aged, Aged, 80 and over, Cohort Studies, Dose-Response Relationship, Drug, Female, Humans, Incidence, Male, Proportional Hazards Models, Quetiapine Fumarate, Retrospective Studies, Risk Factors, Sex Factors.
Abstract
Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.
DOI: 10.1016/j.amjopharm.2012.11.001
PubMed: 23217531
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A01
- to stream PubMed, to step Curation: 000A01
- to stream PubMed, to step Checkpoint: 000A01
- to stream Ncbi, to step Merge: 001323
- to stream Ncbi, to step Curation: 001323
- to stream Ncbi, to step Checkpoint: 001323
- to stream Main, to step Merge: 001311
- to stream Main, to step Curation: 001280
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="1"><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada. cmarras@uhnres.utoronto.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Herrmann, Nathan" sort="Herrmann, Nathan" uniqKey="Herrmann N" first="Nathan" last="Herrmann">Nathan Herrmann</name></author><author><name sortKey="Anderson, Geoffrey M" sort="Anderson, Geoffrey M" uniqKey="Anderson G" first="Geoffrey M" last="Anderson">Geoffrey M. Anderson</name></author><author><name sortKey="Fischer, Hadas D" sort="Fischer, Hadas D" uniqKey="Fischer H" first="Hadas D" last="Fischer">Hadas D. Fischer</name></author><author><name sortKey="Wang, Xuesong" sort="Wang, Xuesong" uniqKey="Wang X" first="Xuesong" last="Wang">Xuesong Wang</name></author><author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A" last="Rochon">Paula A. Rochon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:23217531</idno><idno type="pmid">23217531</idno><idno type="doi">10.1016/j.amjopharm.2012.11.001</idno><idno type="wicri:Area/PubMed/Corpus">000A01</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A01</idno><idno type="wicri:Area/PubMed/Curation">000A01</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A01</idno><idno type="wicri:Area/PubMed/Checkpoint">000A01</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A01</idno><idno type="wicri:Area/Ncbi/Merge">001323</idno><idno type="wicri:Area/Ncbi/Curation">001323</idno><idno type="wicri:Area/Ncbi/Checkpoint">001323</idno><idno type="wicri:Area/Main/Merge">001311</idno><idno type="wicri:Area/Main/Curation">001280</idno><idno type="wicri:Area/Main/Exploration">001280</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="1"><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada. cmarras@uhnres.utoronto.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Herrmann, Nathan" sort="Herrmann, Nathan" uniqKey="Herrmann N" first="Nathan" last="Herrmann">Nathan Herrmann</name></author><author><name sortKey="Anderson, Geoffrey M" sort="Anderson, Geoffrey M" uniqKey="Anderson G" first="Geoffrey M" last="Anderson">Geoffrey M. Anderson</name></author><author><name sortKey="Fischer, Hadas D" sort="Fischer, Hadas D" uniqKey="Fischer H" first="Hadas D" last="Fischer">Hadas D. Fischer</name></author><author><name sortKey="Wang, Xuesong" sort="Wang, Xuesong" uniqKey="Wang X" first="Xuesong" last="Wang">Xuesong Wang</name></author><author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A" last="Rochon">Paula A. Rochon</name></author></analytic><series><title level="j">The American journal of geriatric pharmacotherapy</title><idno type="eISSN">1876-7761</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antipsychotic Agents (administration & dosage)</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Benzodiazepines (administration & dosage)</term><term>Benzodiazepines (adverse effects)</term><term>Benzodiazepines (therapeutic use)</term><term>Cohort Studies</term><term>Dementia (drug therapy)</term><term>Dibenzothiazepines (administration & dosage)</term><term>Dibenzothiazepines (adverse effects)</term><term>Dibenzothiazepines (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Proportional Hazards Models</term><term>Quetiapine Fumarate</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Risperidone (administration & dosage)</term><term>Risperidone (adverse effects)</term><term>Risperidone (therapeutic use)</term><term>Sex Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term><term>Benzodiazepines</term><term>Dibenzothiazepines</term><term>Risperidone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Benzodiazepines</term><term>Dibenzothiazepines</term><term>Risperidone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Benzodiazepines</term><term>Dibenzothiazepines</term><term>Risperidone</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Proportional Hazards Models</term><term>Quetiapine Fumarate</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Sex Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Anderson, Geoffrey M" sort="Anderson, Geoffrey M" uniqKey="Anderson G" first="Geoffrey M" last="Anderson">Geoffrey M. Anderson</name><name sortKey="Fischer, Hadas D" sort="Fischer, Hadas D" uniqKey="Fischer H" first="Hadas D" last="Fischer">Hadas D. Fischer</name><name sortKey="Herrmann, Nathan" sort="Herrmann, Nathan" uniqKey="Herrmann N" first="Nathan" last="Herrmann">Nathan Herrmann</name><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A" last="Rochon">Paula A. Rochon</name><name sortKey="Wang, Xuesong" sort="Wang, Xuesong" uniqKey="Wang X" first="Xuesong" last="Wang">Xuesong Wang</name></noCountry><country name="Canada"><noRegion><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001280 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001280 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23217531
|texte= Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23217531" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |